Physicians underdiagnose and undertreat obesity in ishemic heart disease patients: data from the HOLEM Study Group

Eyal Leibovitz1, Yariv Gerber, Maximo Maislos

  • 1Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer, Israel.

Insights

Physicians rarely documented obesity or recommended weight loss for ischemic heart disease patients. This oversight in medical records highlights a gap in addressing obesity as a critical cardiovascular disease risk factor.

Area of Science:

  • Cardiology
  • Public Health
  • Medical Informatics

Background:

  • Obesity is a significant, independent risk factor for ischemic heart disease (IHD).
  • Obesity negatively impacts other cardiovascular disease risk factors.
  • Effective management of IHD requires addressing all contributing risk factors, including obesity.

Purpose of the Study:

  • To assess physician awareness and documentation of obesity in patients with IHD.
  • To examine how obesity is recorded in hospital discharge letters for IHD patients.
  • To evaluate the frequency of weight loss recommendations for obese IHD patients.

Main Methods:

  • Analysis of the HOLEM database, focusing on discharge letters from 2994 IHD patients.
  • Data collected from four Israeli hospitals between 1998-2000.
  • Review included documentation of risk factors, treatment, and verification of diagnosis and risk status post-discharge.

Main Results:

  • 32% of IHD patients were obese (BMI ≥ 30 kg/m²).
  • Obesity was noted in discharge letters for only 39.6% of obese and 65.8% of morbidly obese patients.
  • Weight loss was recommended in just 15% of obese patients' discharge letters; notation correlated with BMI and number of risk factors.

Conclusions:

  • Most obese IHD patients' discharge letters failed to document weight status.
  • Weight loss recommendations were infrequently provided to obese IHD patients.
  • There is a significant gap in addressing obesity management within IHD patient discharge summaries.
Abstract

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...